Update journal reading
指導老師 : 陳玉昆醫師
報告者 : R2 林雁秋
報告者： R2 林雁秋
1. Introduction
• First reported case of osteonecrosis of the jaw (ONJ) : Marx 2003
– Occurring in patients with multiple myeloma treated with intravenously administered
bisphosphonate
• Bisphosphonate : treat bone resorbing diseases
– multiple myeloma and bone metastasis
– whose typical origins are breast cancer and prostate cancer
• Specific target cell of BP : osteoclast
• Nitrogen-containing BP (nBP) has more potent ability to inhibit mineral dissolution and higher potency to induce BRONJ than early BP without nitrogen-containing side- chain
• The half life of BP in humans : about 10 years
2. Risk factors for BRONJ
risk factors
• glucocorticoids (GCs), anti-cancer drugs, alcohol, smoking, and malnutrition, tooth extraction and other surgical procedures
Tooth extraction
• Tooth extraction raised the incidence of BRONJ about 8-fold
• Spontaneous BRONJ
– The lingual side of the alveolus in mandible , which is thought to be triggered by an injury on the mucosa.
– palatal torus and mandibular torus
Glucocorticoids
• GCs + BP raise the risk for BRONJ
– GCs suppress the activities of inflammatory cells and immune cells to make the patients immunocompromized.
– GCs not only activate the osteoclasts, but
also inhibit the osteoblasts, the long-term use of GCs induce osteoporosis. That is why
patients undergoing GC therapy are also administered BP to prevent osteoporosis.
3. Diagnostic criteria and stage
classification of BRONJ
Criteria and stage
• 2007 American Association of Oral and Maxillofacial Surgeons
– (1) current or previous treatment with a BP – (2) exposed bone in the maxillofacial region
that has persisted for more than 8 weeks DD : chronic suppurative osteomyelitis
– (3) no history of radiation therapy to the jaws
DD : ORN
Criteria and stage
• Staging classification of BRONJ (2007)
– Stage 1 : only an exposure of the bone without infectious signs.
– Stage 2 : not only a bone exposure, but also
inflammatory symptoms by bacterial infection such as pain and swelling.
– Stage 3 : when the lesion extends to the jaw itself
beyond the alveolar level , where the bone necrosis or osteolysis may extend to the inferior border of
mandible with or without extraoral fistula and pathological fracture.
Criteria and stage
Criteria and stage
• Stage 0 (2009)
– no clinical evidence of necrotic bone, but nonspecific clinical findings and symptoms
– diffuse alveolar swelling, gingival redness, or internal dental fistula
Criteria and stage
4. Relationship between stage 0 and suppurative
osteomyelitis of the jaw
• Kos et al. Actinomyces
• Ganguli et al. Staphylococcus aureus
• Hansen et al. Actinomyces
• not observed in suppurative osteomyelitis
• CT or cone beam CT seems to be useful to detect these initial changes in the bones for the early diagnosis of stage 0.
5. Mechanism of nitrogen-
containing BP actions
Small GTPases
• Small GTPases cytoskeletal arrangement,
vesicular trafficking, and membrane ruffling which are involved in the processes of bone resorption by osteoclasts, including their migration to bones,
adhesion on bone surface and transportation of bone-resorbing enzymes to the ruffled border.
• Therefore, the inhibition of FPP synthase with nBP can prevent osteoclasts from destructing the bones
• Weinstein et al.
– P’t with nBP : few osteoclasts , giant, hypernucleated (with 20–40 nuclei)
– nBP protracts the apoptosis of osteoclasts, where cell fusion continues to generate the distinctive
morphology such as giantism and hypernucleation.
• These data suggest that nBP brings about the functional disorder, rather than the depletion, of osteoclasts.
6. Other target cells of BP
Osteoblasts
• The cooperation of osteoclasts with osteoblasts, which is called “coupling”
– osteoclastic bone resorption can release
some growth factors buried in the bone, which stimulate osteoblasts to make bones
Osteocytes
• Allen and Burr beagle dogs +daily oral alendronate for 3 years
– necrotic bone matrix (25%) : mandible.
– non-viable bone matrix showed empty lacunae without osteocytes
• osteocytes are thought to provide a signal to osteoclasts to clean up the necrotic bones
• It is likely that the micronecrosis of the bone may accumulate in large amounts because of the lack of osteocyte–osteoclast communication
Vascular endothelial cells
• BP inhibits bone angiogenesis by suppressing the growth of vascular
endothelial cells to result in avascular necrosis of the bone.
Keratinocytes
• nBP decreased the number of p63-positive keratinocyte progenitor cells and
prevented the gingival fibroblasts from producing keratinocyte growth factor (KGF)
Macrophages/monocytes
• osteoclasts differentiate from
macrophage/monocyte lineage, it is
plausible that nBP inhibits the activity of macrophages.
7. Why does BRONJ occur
in the jaws?
• (1) The turnover rate of jaws, especially alveolar bones, is so rapid
• (2) Jaws have teeth and gum that may become an easy entrance for bacterial infection
Bone turnover rate
• The remodeling rates of the cortical bone in the jaw are 10–20 times higher than in the cortex of iliac crest in humans
Vulnerability of the jaw to bacterial infection
• Jaw seems to be the most liable to
bacterial infection since mucosa covering the alveolar bone is very thin and
vulnerable, and teeth easily become a
pathway for bacteria from the outside into the bone
9. Pathophysiological
mechanism of BRONJ
10. Treatment of BRONJ
• Stage 3 : surgical removal of the jaw which contains the necrotic bones
• Stage 1 or stage 2 : conservative therapy
– local irrigation with saline or the use of oral antimicrobial rinse.
Drug holiday
• Discontinuation of BP therapy
– seems to be effective to restore bone turnover of the jaw and support the treatment of
BRONJ.
– more than 3 months before tooth extraction if the patients have received oral BP therapy for more than 3 years.
Hyperbaric oxygen
• The efficacy of HBO in the treatment of BRONJ has not yet been elucidated,
• It is expected to improve the hypoxia
condition in the jaw and generate reactive oxygen species (ROS) to stimulate the
differentiation and activity of osteoclasts
Teriparatide (recombinant human parathyroid hormone 1–34)
• Teriparatide consists of 1–34 amino acids of recombinant human parathyroid
hormone (PTH) (a full PTH includes 84 amino acids), and has been used for the treatment of GC-induced osteoporosis.
Teriparatide (recombinant human parathyroid hormone 1–34)
• Treatment of BRONJ, teriparatide may
cause activation of osteoblasts to restore the bone turnover once inhibited with nBP, and
• Promote the production of receptor activation of nuclear factor-kB ligand
(RANKL) from osteoblasts to reactivate osteoclasts.
